

This article was published in *Crystal Growth and Design*, 16(7), 3748-3755, 2016
<http://dx.doi.org/10.1021/acs.cgd.6b00262>

**Protein crystallization as a process step in a novel meso oscillatory flow reactor:
study of lysozyme phase behavior**

Filipa Castro^{1,2}, António Ferreira¹, José A. Teixeira² and Fernando Rocha¹

1. LEPABE - Laboratory for Process Engineering, Environment, Biotechnology and Energy, Faculty of Engineering of the University of Porto, Rua Roberto Frias, s/n, 4200-465 Porto, Portugal.

2. CEB - Centre for Biological Engineering, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal.

Mailing addresses:

Faculty of Engineering of the University of Porto, Rua do Dr. Roberto Frias, s/n, 4200-465 Porto, PORTUGAL

Tel.: +351 22 508 16 87

E-mail: filipaj@fe.up.pt

Abstract

In the present work, it is reported for the first time the study of the applicability of a novel meso oscillatory flow reactor (meso-OFR) for protein crystallization as a process step. Crystallization assays carried out in the designed device enabled to derive a two-dimensional lysozyme phase diagram (lysozyme concentration against sodium chloride concentration). Results evidence the formation of several types of crystals (different size and shape), with a strong influence of salt concentration on crystal shape. Results also show that lysozyme remains active at the end of the experiments. Furthermore, it was possible to verify the reduction of the metastability zone when compared to lysozyme crystallization conducted under quiescent conditions. Induction times were also measured by online monitoring of the turbidity of the crystallization solution, obtained

1
2
3 values being between 41 and 900 minutes. Beyond providing improved understanding
4
5 of protein phase behavior under oscillatory flow mixing, the results are very promising
6
7 regarding the feasibility of the designed methodology for protein crystallization as a
8
9 process step.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Protein crystallization has been focused on the production of diffraction-quality single crystals for protein structure determination by crystallography¹⁻³. Research conducted during the last years has led to improved methodologies for the production of high-quality protein crystals allowing obtaining high-quality X-ray diffraction patterns, and leading thus to information on structure biology³. However, protein crystallization also offers many advantages as a means of protein purification at the industrial scale. Compared to conventional purification techniques, such as chromatography, crystallization is a cost-effective alternative since high-purity proteins can be obtained from a single-step operation^{2,4-8}. Further, protein crystals have a longer storage life and greater purity than the dissolved form, which opens up the number of potential applications for the pharmaceutical industry, from formulation and storage of proteins to drug delivery^{1,4,9}.

Unlike protein structure determination, where single, large, stable and well-diffracting crystals are required and usually obtained by slow-growing processes, rapid and quantitative crystallization is needed for large-scale protein purification processes. As most of the industrial processes, recovery yield as well as purity must be high and the crystallization time low, so that growth kinetics should be fast (hours)^{2,4,10,11}. Moreover, reagents must be inexpensive, compounds should be of pharmaceutical grade and proteins must not lose their potency after crystals are redissolved^{1,11}. In contrast to structural analysis, large single crystal shape is not as important, but crystals with a certain size, shape and mechanical strength are desirable, in order to be easily separated from their mother liquor, namely by filtration or centrifugation^{1,2,10-12}.

Identification of crystallization conditions of a protein is still difficult, particularly for purification purposes where the crystallization step has to meet specific

1
2
3 requirements^{4,11,13}. It requires knowledge about the thermodynamic properties of the
4
5 protein solution, concentration of the protein, temperature and characteristics of the
6
7 solvent (e.g., pH, ionic strength, buffer concentration and identity, and any
8
9 additives)^{3,14}. The traditional method to study protein solubility, in response to different
10
11 operating conditions, is to construct a phase diagram, commonly protein concentration
12
13 against precipitant agent concentration. A phase diagram is divided by the solubility
14
15 curve into two areas corresponding to undersaturated and supersaturated state of a
16
17 protein solution. The supersaturated area comprises of the metastable, nucleation and
18
19 precipitation zones^{3,10,11,13,14}. In the nucleation and precipitation zones the protein is
20
21 either crystalline or precipitated, whereas in the metastable zone the probability of
22
23 nucleation occurrence is very low but already existing crystals could grow³. However,
24
25 complete phase diagrams for prediction of protein crystallization are rarely available
26
27 and crystallization conditions are usually found by a trial-and-error approach. The few
28
29 reports published include the work of Hekmat¹² and Smejkal⁵ on the crystallization of
30
31 lysozyme, the works of Smejkal⁹ and Hebel¹⁵ both on the crystallization of therapeutic
32
33 antibodies and more recently the study conducted by Huettmann¹¹ on the crystallization
34
35 of interferon gamma.
36
37
38
39
40
41
42

43 While protein crystallization is usually performed under quiescent conditions, protein
44
45 crystallization as a process step requires a minimum of agitation. Otherwise crystals
46
47 sink to the bottom, grow into each other and the crystal growth is diffusion limited
48
49 leading to long process durations and/or low yields^{9,16}. Studies concerning the influence
50
51 of the type and degree of agitation on protein crystallization can be found in the
52
53 literature. A reduced nucleation time was observed in an unbaffled stirred vessel¹⁷, in a
54
55 wave shaker¹⁸ and under oscillatory flow¹⁶. Smejkal *et al.*⁵ observed a significantly
56
57 faster onset of the crystallization of lysozyme and Fab-fragment of the therapeutic
58
59
60

1
2
3 antibody Canakinumab in stirred vessels when compared to non-agitated systems.
4
5 Besides, authors verified that further increase of the agitation rate resulted in the
6
7 decrease of lysozyme crystallization onset. In contrast, a prolonged nucleation time was
8
9 verified in a rotary shaker¹⁹ and under mechanical vibration²⁰. Vekilov and
10
11 Rosenberger²¹ suggested that lysozyme growth cessation and deceleration were due to
12
13 convection-enhanced supply of impurities to the interface. Shear forces were also
14
15 related to limit the attachment of lysozyme growth units²².
16
17

18
19 Another key issue concerns the scalability of the process^{1,11}. Protein crystallization on
20
21 process scale is usually performed in stirred tank crystallizers. Commonly suggested
22
23 scale-up criteria such as minimum agitation rate to keep the crystals in suspension or
24
25 impeller tip speed are not always successful and sometimes the scale-up criterion has to
26
27 be based on experimental data^{9,23}. Moreover, large stirred tanks are usually
28
29 characterized by low mixing efficiency that give rise to excess local concentrations⁴,
30
31 and in its turn leads to spontaneous nucleation. Besides, shear stresses exerted by the
32
33 impellers can lead to protein denaturation and damaged crystals^{4,7}. Another important
34
35 concern is the fact that often limited amounts of protein are available, making difficult
36
37 the implementation of experiments on a large scale.
38
39

40
41 So far, only a few reports have been published on protein crystallization as a process
42
43 step. The most prominent example is the industrial implementation of the crystallization
44
45 process of insulin²³. Other examples include studies on the crystallization of lysozyme
46
47 ^{5,12,15,24–26}, ovalbumin¹⁷, L-methionine γ -lyase²⁷, fungal lipases^{10,28} and urate oxidase²⁹.
48
49
50 Studies have also been reported on more complex proteins like monoclonal
51
52 antibodies^{9,11,30}, more difficult to crystallize due to their large size and structural
53
54 flexibility¹⁵. More recently, Neugebauer and Kinast⁷ reported the development of a
55
56 tubular-plug flow crystallizer for the continuous lysozyme crystallization. Although the
57
58
59
60

1
2
3 studies published show the feasibility of protein crystallization as a means of
4 purification, further work is required in order to establish the latter as an alternative to
5
6 the existing downstream processing techniques. A limited number of works were
7
8 performed under well-defined and scalable operating conditions⁷. In addition, some of
9
10 the reports lack information about protein phase behavior, crystallization kinetics and
11
12 yield³¹, and flow conditions²⁹. Furthermore, rather long process durations and/or low
13
14 yields were observed in most cases^{9,16,29-31}.

15
16
17
18
19 In order to overcome some of the gaps observed in common crystallizers, a novel meso
20
21 oscillatory flow reactor (meso- OFR) was developed by members of the present
22
23 research team³². The device is operated under oscillatory flow mixing that has been
24
25 proved to result into significant enhancement in processes such as mass transfer and
26
27 particle mixing^{33,34}, particularly relevant for crystallization processes. Indeed,
28
29 significant enhancement in crystal characteristics and reduction of operation time have
30
31 been reported for the crystallization of hydroxyapatite^{35,36}. In addition, the reactor can
32
33 be easily scaled up by the addition in series of other identical meso-OFR unities. In this
34
35 context, the present work aims to study, for the first time, the applicability of the meso-
36
37 OFR on protein crystallization for purification purposes. Lysozyme was used as a
38
39 protein crystallization model. Like any industrial process it is intended to obtain
40
41 maximum yield and purification, and to achieve this rapidly. Control of crystal size is as
42
43 well important. Optimization with respect to all these criteria has to be based on a
44
45 fundamental understanding of the process, that is, knowledge of the phase diagram and
46
47 kinetics. For this, different experimental conditions were screened by varying protein
48
49 and precipitating agent concentration in order to derive a sufficiently quantitative
50
51 crystallization phase diagram of the protein under study. Induction times were measured
52
53 by online monitoring of the turbidity of the crystallization solution. The obtained
54
55
56
57
58
59
60

1
2
3 crystals were characterized by optical microscopy and their activity was measured.
4
5 Additionally, crystal yield was estimated.
6
7
8
9

10 **Materials and Methods**

11 *Proteins and chemicals*

12
13
14 Chicken egg-white lysozyme was purchased from Sigma-Aldrich (Fluka-62971,
15 Germany, lot #BCBJ2814V) and was used without further purification. One stock
16
17 solution of 0.2 M sodium acetate buffer at pH 4.7 was prepared using sodium acetate
18
19 trihydrate from Sigma-Aldrich (99,5 %, Germany) and glacial acetic acid from Merck
20
21 (100 %, Germany) to adjust the pH. Sodium chloride was obtained from Panreac
22
23 AppliChem (99,5%, Germany). Several lysozyme (5 to 50 mg.mL⁻¹) and sodium
24
25 chloride (2.5 to 6 %(w/v)) solutions were prepared in the sodium acetate buffer solution,
26
27 pH of the sodium chloride solution being posteriorly adjusted with a 1 M hydroxide
28
29 sodium (Pronolab, Portugal) solution. All the solutions were prepared in ultra-pure
30
31 water (Milli Q water, resistivity of 18.2 MΩ.cm⁻¹ at 25 °C) and filtered through a 0.2
32
33 μm cut-off membrane (Sigma-Aldrich, Whatman, Germany). Lysozyme concentrations
34
35 were measured by UV spectroscopy (ScanSpec UV-VIS, Sarspec, Portugal) at 280 nm
36
37 using a known extinction coefficient (2.5 L.g⁻¹.cm⁻¹)⁹.
38
39
40
41
42
43
44

45 *Experimental installation*

46
47 Lysozyme crystallization trials were carried out in the experimental set-up represented
48
49 in Figure 1. It involves the meso-OFR placed vertically, a mixing chamber and a
50
51 measuring cell connected to a spectrophotometer for turbidity measurement. The device
52
53 consists of a 35 cm long and 3 mm internal diameter glass jacketed tube provided with
54
55 smooth periodic constrictions (SPC) and has an approximate volume of 4 mL (Figure
56
57 1). The crystallization solution was oscillated using a piston moved by a stirring motor
58
59 (CAT R100C, United States of America). The oscillating device was custom-built. The
60

1
2
3 reactor is operated under oscillatory flow mixing, controlled by the oscillation
4 frequency (f) and amplitude (x_0) that were fixed at 1.83 Hz and 4 mm, respectively. The
5 value of the amplitude corresponds to the center-to-peak amplitude, and the
6 measurements were performed in the tube without constrictions. Reactants were fed into
7 the set-up by means of a syringe pump (NE-4000, New Era, United States of America).
8 Temperature of the reactants and temperature inside the meso-OFR was regulated by a
9 thermostatic bath (Huber, Ministat 125, Germany) maintained at 20 °C.

Figure 1.

Determination of phase diagram

21
22
23 Batch crystallization experiments with different lysozyme and sodium chloride
24 concentrations were carried out at pH 4.7 and 20 °C. As the conventional microbatch
25 methodology, the solution is undersaturated, saturated or supersaturated at the
26 beginning of each experiment. This allows a more accurate description of phase states
27 with known operating conditions^{3,14}. Experiments were started by the simultaneous
28 injection in the experimental set-up of equal volumes of both lysozyme and sodium
29 chloride solutions. After 24h of incubation, samples were investigated for crystals,
30 precipitates or other structures by optical microscopy (Standard 20, Zeiss, Germany).
31 The supernatant was filtered and diluted with ultra-pure water for lysozyme
32 concentration determination by UV absorbance ($\lambda = 280$ nm). This procedure was
33 carried out at least three times for each initial supersaturation ($Si = \frac{C_{lysozyme\ initial}}{Solubility_{lysozyme}}$).
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51 Then, a phase diagram was assembled (Figure 2).

Figure 2.

Induction time

52
53
54
55
56
57 Induction time (t_{ind}) is known as the period between the establishment of supersaturation
58 and the detection of a new phase^{37,38}. Increase of the crystals number in solution can be
59
60

1
2
3 detected by measuring the turbidity of the crystallization solution, once the formation of
4
5 a crystal suspension is expected to decrease light transmission. The induction time can
6
7 thus be determined by using the change in the transmission of light. In this way, on-line
8
9 measurement of the turbidity of the crystallization solution was carried out with a
10
11 spectrometer (ScanSpec UV-VIS, Sarspec, Portugal) at 400 nm in order to monitor the
12
13 crystallization process:
14
15

$$16 \quad \tau = \frac{2.303}{d} \times A \quad (1)$$

17 where τ = turbidity;

18 d = scattering path length (path length of the measuring cell being 0.4 cm);

19 A = absorbance.
20
21
22
23
24

25 Absorbance measurements of the crystallization solution allowed to build the turbidity
26
27 profile curves, using Equation (1), for each experimental condition studied. Figure 3
28
29 shows a typical turbidity profile curve. During the induction time that precedes the
30
31 formation of stable nuclei, turbidity is almost constant, while nucleation and growth of
32
33 lysozyme crystals resulted in an abrupt increase in the turbidity. In this way, induction
34
35 times were derived by the intersect values, on the axis time, of the tangent to the first
36
37 rapid increase in the turbidity profile curve as illustrated in Figure 3:
38
39
40

41 **Figure 3.**
42

43 *Lysozyme activity*

44
45 Enzymatic activity of the lysozyme crystals obtained was determined by
46
47 spectrophotometry and compared to the enzymatic activity of the initial lysozyme
48
49 solution. The rate of lysis of *Micrococcus lysodeikticus* was determined, one unit being
50
51 equal to a decrease in turbidity of 0.001 per minute at 450 nm at pH 6.25 and 25°C.
52
53
54
55

56 **Results and Discussion**

57 *Lysozyme phase behavior* 58 59 60

1
2
3 Batch crystallization experiments carried out in the meso-OFR enabled to derive
4 lysozyme phase behavior under oscillatory flow mixing at 20 °C and pH 4.7 (Figure 4).
5
6 The solubility^{39,40} and the metastability⁴¹ curves were drawn based on the data available
7
8 in the literature at quiescent conditions. Clear solutions above the solubility curve were
9
10 indicative of the metastable region, once in spite of being supersaturated these solutions
11
12 were not able to produce crystals. As expected, increasing concentrations of both
13
14 lysozyme and sodium chloride above the metastability curve led to crystallization and
15
16 further increase to simultaneous crystallization and precipitation. Several types of
17
18 crystals were observed, from tetragonal, orthorhombic and needle-shaped crystals to
19
20 microcrystals and precipitate, depending on both reactants concentration but mostly on
21
22 salt concentration (Figure 5). For sodium chloride concentrations below and equal to
23
24 3% (w/v), essentially tetragonal crystals were observed. One can also verify that crystals
25
26 with different sizes (about 5 to 15 μm) and aggregated crystals were obtained. For
27
28 sodium chloride concentration of 4% (w/v) and lysozyme concentration between 15 and
29
30 25 $\text{mg}\cdot\text{mL}^{-1}$, samples were constituted by well-defined tetragonal and orthorhombic
31
32 crystals with typical size around 10 μm and needle-shaped crystals. Images also
33
34 demonstrate the generation of aggregated microcrystals (with typical size about 3 μm)
35
36 for higher lysozyme concentration. For high concentrations of sodium chloride ($\geq 5\%$
37
38 (w/v)) and low concentration of lysozyme (10 to 15 $\text{mg}\cdot\text{mL}^{-1}$) mainly needles with
39
40 regular structure and shape were formed, while increasing lysozyme concentration led
41
42 to precipitation.
43
44
45
46
47
48
49
50
51

52 **Figure 4.**

53 **Figure 5.**

54
55
56 As known, crystallization of a protein involves reduction of the solubility of the protein,
57
58 namely by the addition of precipitant agents³. In the case of sodium chloride, the
59
60 solvation layer around protein molecules is reduced, giving thus rise to solubility

1
2
3 decrease. In this way, a direct relationship was verified between salt concentration and
4 the appearance of lysozyme crystals. Results obtained also demonstrated a strong
5 influence of salt concentration on the shape of lysozyme crystals. Under quiescent
6 conditions, experimental conditions studied should only lead to the formation of
7 tetragonal lysozyme crystals³⁹⁻⁴¹. However, for concentrations of sodium chloride equal
8 and superior to 4% (w/v) samples contain needle-shaped crystals. Bhamidi *et al.*⁴²
9 suggested that needles were an unstable polymorph of lysozyme that slowly would
10 convert to the tetragonal form. However, observations done on the collect suspensions
11 kept during several months did not prove this hypothesis for all the cases.

12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
In the present work lysozyme crystals are subjected to fluid shear forces induced by
oscillatory flow mixing and solid-liquid interfaces. Lysozyme crystals collide with parts
of the glass walls of the meso-OFR and with each other. In this way, crystalline
fragments could be created by attrition leading to secondary nucleation that gives rise to
excess nucleation and suppresses growth, and in its turn lead to small size crystals⁴³.
Indeed, protein crystals are generally more fragile than crystals of inorganic and small
organic molecules because of their high solvent content⁴⁴, so that they are highly likely
to fracture during collision with each other or the crystallization equipment.
Experimental results suggest the occurrence of a strong nucleation, since most of the
experimental conditions studied led to the formation of a high number of small crystals
and crystals with different sizes (Figure 5).

As shown on Figure 5, some aggregation could be observed. In what concerns protein
crystals aggregation, literature reports many factors that can induce particle aggregation.
Kusters *et al.*⁴⁵ suggested that aggregation for lysozyme crystals with a diameter
approximately in the range 1-100 μm is mainly induced by shear forces according to its
Kolmogorov microscale. Other studies⁴⁶ demonstrated that shear alone do not cause

1
2
3 aggregation although prolonged exposure resulted in some minor, reversible
4
5 aggregation. In the present work, besides the fact that the lysozyme crystals have an
6
7 average size in the order of 10 μm (see Table 2), they are also subjected to shear stress,
8
9 which may explain their aggregation.
10
11

12 *Lysozyme activity*

13
14 Regarding the activity of the crystals collected, the results revealed that the protein
15
16 collected is still active, since most of the samples exhibited at least 80% of activity
17
18 when compared to the initial lysozyme solution.
19
20

21
22 It is commonly believed that denaturation is a prerequisite for aggregation, once small
23
24 perturbations in protein structure may expose hydrophobic surfaces, causing self-
25
26 interactions and consequential aggregation⁴⁶. According to the literature⁴⁷, long
27
28 exposure time at solid-liquid interfaces⁴⁸ and a moving gas-liquid interface^{46,49–52} can
29
30 cause damage to proteins. It has also been reported that this phenomenon is mainly due
31
32 to the hydrophobic character of such interfaces⁴⁶. In the meso-OFR, lysozyme crystals
33
34 are subjected to fluid shear forces and solid-liquid interfaces. Furthermore, they are
35
36 exposed to air-liquid interfaces, although there have been attempts to minimize them,
37
38 once reactants were carefully injected in the system to avoid bubbles and the reactor
39
40 was almost completely full. Given the little loss of activity, the aggregation observed
41
42 may be mainly explained by exposure to shear stress as already suggested above.
43
44
45
46
47
48

49 *Metastability curve determination*

50
51 Based on lysozyme phase behavior (Figure 4), it was possible to determine the
52
53 metastability curve based on the minimum sodium chloride concentration needed for
54
55 nucleation at different lysozyme concentrations. Given the uncertainty associated to the
56
57 experimental results and the stochastic nature of nucleation, a potential range for the
58
59 metastability curve was represented (error bars). These results, as well as the solubility
60

and metastability curves reported in the literature for microbatch experiments^{39,40} were linearized (see Figure 6) according to Martins *et al.*⁴⁰ equation:

$$C_{lysozyme} = A \exp\left(\frac{B}{C_{NaCl}}\right) \quad (2)$$

where $C_{lysozyme}$ is the lysozyme concentration in $\text{mg}\cdot\text{mL}^{-1}$ and C_{NaCl} is the concentration of sodium chloride in percentage units (w/v). The values of the constants A and B that best fit the experimental results are given in Table 1.

Figure 6.

Table 1. Values of A and B constants from the linearization of both experimental metastability and theoretical solubility and metastability curves of lysozyme at 20 °C and pH 4.7.

Linearized curve	A	B	r ²
Solubility ^{39,40}	0.354	8.45	0.973
Metastability ⁴¹	3.744	6.19	0.983
Metastability – meso-OFR	1.887	7.52	0.970

According to Figure 6 and Table 1, metastability data can be described by the exponential relationship proposed by Martins *et al.*⁴⁰, used for the description of lysozyme solubility curve with sodium chloride as the precipitant agent.

Reduction of the metastability zone

From the experimental and literature results (Figures 4 and 6), it was possible to illustrate the undersaturation, metastable, crystallization and precipitation zone (Figure 7), hence giving information about the relevant range of precipitant and protein concentration for lysozyme crystallization in the meso-OFR at 20 °C and pH 4.7.

Figure 7.

Graphical representation of the experimental metastability curve and both theoretical solubility and metastability curves clearly illustrates the reduction of the metastability zone when performing lysozyme crystallization under oscillatory flow mixing (Figure 7). For instance, for a lysozyme concentration of $15 \text{ mg}\cdot\text{mL}^{-1}$, crystals were observed at $S_i = 5.4$ with oscillatory flow mixing, while under quiescent conditions appearance of crystals is only expected for S_i values superior or equal to 6.3 (metastability data).

1
2
3 Under agitation, collision between protein molecules is increased, increasing thus
4 nucleation probability. As a result, metastability region is reduced leading to the
5 occurrence of nucleation at lower supersaturation levels. Hence, crystallization
6 conditions that normally do not produce crystals may become successful using
7 oscillatory flow mixing. This could be particularly interesting for proteins with a limited
8 range of crystallization conditions, since the probability of crystals appearance can be
9 increased under oscillatory flow mixing.
10
11
12
13
14
15
16
17
18

19 20 21 *Induction time*

22
23 Measured induction time was plotted as a function of the initial supersaturation, S_i , for
24 the experimental conditions studied (Figure 8).
25
26

27 28 **Figure 8.**

29
30 Nucleation is time-critical during protein crystallization processes as it determines the
31 onset of crystallization. Further, nucleation controls crystal product quality aspects such
32 as the kind of solid state and crystal size distribution³⁷. In this study, crystallization
33 onset was evaluated through induction time measurements. According to Figure 8,
34 typical values for induction time are between 41 to 900 minutes depending on the initial
35 supersaturation S_i . It further refers that tetragonal crystals were essentially obtained at
36 low S_i , i.e. at large induction times, while needles and precipitates were preferentially
37 formed at high S_i , i.e. at low induction times. One can also verify that for sodium
38 chloride concentrations of 4 and 5% (w/v), induction time decreases as S_i increases,
39 while no direct relationship between S_i and induction time was evidenced for a sodium
40 chloride concentration of 3% (w/v). It is important to mention that the value of the
41 induction time depends strongly on the methodology employed to detect the formation
42 of new nuclei. In this study, measurement of the induction time is based on the detection
43 of an abrupt increase in the turbidity of the crystallization solution, thereby a
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 considerable number of crystals have to be formed to detect a significant increase in the
4
5 turbidity of the solution. For the highest sodium chloride concentrations, experiments
6
7 were characterized by a strong nucleation giving rise to a high number of crystals in
8
9 solution, and in turn an important increase in the turbidity of the solution. In contrast,
10
11 lower sodium chloride concentration experiments did not lead to a noteworthy change
12
13 in the turbidity of the solution, in particular when only tetragonal crystals were
14
15 observed. For those cases, crystallization solutions kept relatively clear throughout the
16
17 experiment despite the presence of crystals in solution. This partly explains the large
18
19 variation in the induction time values (error bars - standard deviations from at least three
20
21 independent experiments), which can also be explained by the stochastic nature of
22
23 nucleation and the low probability that nuclei form at low supersaturations. From Figure
24
25 8, one can verify that for the same sodium chloride concentrations (4% (w/v)) and lower
26
27 S_i , induction times are shorter than the values reported in the literature⁵. Indeed, Smejkal
28
29 *et al.*⁵ related crystallization onsets from 350 to 570 minutes (stirrer speeds from 400 to
30
31 200 rpm, respectively) in a 6 mL-scale stirred tank for $S_i = 9.7$, while we observed
32
33 values of 80 and 338 minutes for S_i of 8.9 and 7.1, respectively. As already mentioned,
34
35 the efficient oscillatory mixing mechanism developed in the meso-OFR leads to
36
37 enhanced mass transfer, minimizing thus diffusion limitations that were reported to be
38
39 the main bottleneck in the lysozyme crystallization process in non-agitated systems⁵.
40
41

42 43 44 45 46 47 48 *Summary of experimental conditions*

49
50 Table 2 summarizes the experimental crystallization conditions studied as well as the
51
52 respective crystals characteristics.
53
54
55
56
57
58
59
60

Table 2. Experimental conditions for lysozyme crystallization as a process step in the meso-OFR at 20 °C and pH 4.7 and under agitation conditions of $f = 1.83$ Hz and $x_0 = 4$ mm.

[NaCl] % (w/v)	[Lysozyme] (mg.mL ⁻¹)	S _i	Typical crystal size (μm)	Crystal shape	Crystal yield (%)	Relative activity (%)	Inductio n time (min)
2.5	50	33,3	10 ± 4.6	Tetragonal	-	-	-
3	25	3,4	9.3 ± 4.0	Tetragonal	47.5 ± 11.9	>85	528 ± 239
	30	4,1	9.8 ± 3.9		43.6 ± 21.5		465 ± 15
	35	4,8	8.4 ± 3.4		36.2 ± 22.7		735 ± 135
	40	5,5	7.6 ± 4.1		76.0 ± 12.5		552 ± 19
4	15	5,4	6.5 ± 2.9; 10-50*	Tetragonal,	20,6	>80	772 ± 106
	20	7,1	13 ± 8.8; ≈ 20*	orthorhombic and	40,1 ± 12.9		338 ± 60
	25	8,9	10 ± 5.1; ≈ 30*	needle	50,5 ± 14.6		80
	30	10,7	3.4 ± 2.3	Microcrystals	52,1 ± 47.5		41 ± 1
5	10	5,5	10 - 15	Needle	36,3 ± 4.1	>85	917 ± 34
	15	8,3	≈ 15		8,2 ± 4.2		566
	20	11,0	-		Precipitate		13,9 ± 4.1
6	10	6.7	20 - 50	Needle	-	-	-

*these values correspond to the typical value of the length of the needles, their width being in the order of 1 to 2 μm

According to Table 2, criteria for protein crystallization as a process step were fulfilled¹, since well-defined lysozyme crystals with a typical size around 10 μm were formed for low reagents concentrations. In addition, lysozyme crystals maintained their activity at the end of the process, since for most of the experimental conditions tested collected crystals exhibited at least 80% of activity. Further, crystallization process was relatively fast, since for certain operating conditions it was possible to detect the appearance of crystals after a few minutes. Regarding crystal yield, it was estimated using the following equation:

$$yield (\%) = \frac{C_{lysozyme\ initial} - C_{lysozyme\ final}}{C_{lysozyme\ initial}} * 100 \quad (3)$$

where $C_{lysozyme\ initial}$ and $C_{lysozyme\ final}$ are the initial and final lysozyme concentration estimated through UV absorbance ($\lambda = 280$ nm), respectively. In general the amount of crystals formed is low and further optimization is required, since yields of about 70% have been reported in the literature⁵. For certain experimental conditions, it was not possible to evaluate precisely the size of the crystals, namely when needles and

1
2
3 precipitates were formed. Overlapping of the needles and small size and amorphous
4
5 nature of precipitates prevented a proper assessment of their size.
6
7
8
9

10 **Conclusion**

11
12 The present work reports for the first time the study of lysozyme phase behavior in a
13 novel meso oscillatory flow reactor (meso-OFR). For this, various experimental
14 conditions were screened by varying lysozyme and sodium chloride concentration at pH
15 4.7 and $T = 20\text{ }^{\circ}\text{C}$ and under fixed agitations conditions ($f = 1.83\text{ Hz}$ and $x_0 = 4\text{ mm}$).
16
17 The results obtained enabled the elaboration of a two-dimensional (lysozyme
18 concentration against sodium chloride concentration) phase diagram of lysozyme. It was
19 possible to observe several types of crystals, from tetragonal, orthorhombic and needle-
20 shaped crystals, to microcrystals and precipitates. Results further suggest a strong
21 influence of salt concentration on the shape of lysozyme crystals. Furthermore,
22 lysozyme crystals formed remain active at the end of the experiments. It was also shown
23 that oscillatory flow mixing promotes nucleation at low supersaturation, since results
24 evidenced the reduction of the metastable zone and low induction times.
25
26 This study may thus provide improved understanding of protein phase behavior under
27 agitation, in particular under oscillatory flow mixing. Although further optimization is
28 still required, especially regarding yield and control of crystals' characteristics (size and
29 morphology), results are very promising regarding the applicability of the designed
30 meso-OFR for protein crystallization as a process scale. Indeed, oscillatory flow mixing
31 can induce nucleation in conditions where nucleation normally (quiescent conditions)
32 does not occur, which can be particularly interesting from an industrial point of view.
33
34
35
36
37
38
39
40

41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Acknowledgements

1
2
3 This work was financially supported by the European Regional Development Fund
4 (FEDER) through COMPETE 2020 - Operational Programme Competitiveness and
5 Internationalization (POCI) (UID/EQU/00511/2013-LEPABE - Laboratory for Process
6 Engineering, Environment, Biotechnology and Energy – EQU/00511; POCI-01-0145-
7 FEDER-006684) and by national funds through FCT –Portuguese Foundation for
8 Science and Technology - under the projects: UID/BIO/04469/2013; IF exploratory
9 project [IF/01087/2014]; Postdoctoral Fellowship [SFRH/BPD/96132/2013]. A.
10 Ferreira is an Investigator FCT (IF/01087/2014).
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure Captions

Figure 1. Schematic representation of the experimental set-up for lysozyme crystallization experiments with: OFR-SPC – oscillatory flow reactor provided with periodic constrictions; D - internal tube diameter; d_o - internal diameter in the constrictions; L_1 - convergent-divergent section length; L_2 - straight section length; R_c - radius of the curvature of the sidewall of the convergent section and R_d - radius of the curvature of the sidewall of the divergent section.

Figure 2. Schematic representation of the procedure employed for the generation of lysozyme phase diagram in the meso-OFR at 20 °C and pH 4.7 and under agitation conditions of $f = 1.83$ Hz and $x_0 = 4$ mm.

Figure 3. Typical turbidity profile obtained during crystallization experiments (lysozyme 30 mg.mL⁻¹, NaCl 4% (w/v), pH 4.7 and $T = 20$ °C and under agitation conditions of $f = 1.83$ Hz and $x_0 = 4$ mm).

Figure 4. Lysozyme phase behavior in the meso-OFR at pH 4.7 and 20 °C under agitation conditions of $f = 1.83$ Hz and $x_0 = 4$ mm.

Figure 5. Lysozyme crystals obtained in the meso-OFR at pH 4.7 and 20 °C under agitation conditions of $f = 1.83$ Hz and $x_0 = 4$ mm. Lysozyme concentrations used are mentioned in each picture.

Figure 6. Linearized metastability and solubility curves at 20 °C and pH 4.7 and under agitation conditions of $f = 1.83$ Hz and $x_0 = 4$ mm. Solubility and metastability curves were obtained by curve fitting from data reported in the literature³⁹⁻⁴¹.

Figure 7. Lysozyme phase diagram in the meso-OFR at pH 4.7 and 20 °C under agitation conditions of $f = 1.83$ Hz and $x_0 = 4$ mm.

1
2
3 **Figure 8.** Induction time as a function of the initial supersaturation S_i for different
4 sodium chloride concentrations: 3% (w/v), 4% (w/v) and 5% (w/v). The error bars are
5 standard deviations from at least three independent experiments. Smejkal *et al.* (2013)
6 data was obtained in a stirred tank reactor of 6 mL for different stirrer speeds from 200
7 to 400 rpm with sodium chloride concentration of 4% (w/v) and lysozyme concentration
8 of 50 mg.mL⁻¹.
9

17 **Table Captions**

10
11
12
13
14
15
16
17
18
19
20 **Table 1.** Values of A and B constants from the linearization of both experimental
21 metastability and theoretical solubility and metastability curves of lysozyme at 20 °C
22 and pH 4.7.
23
24
25

26
27
28 **Table 2.** Experimental conditions for lysozyme crystallization as a process step in the
29 meso-OFR at 20 °C and pH 4.7 and under agitation conditions of $f = 1.83$ Hz and $x_0 = 4$
30 mm.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

- (1) Etzel, M. R. In *Process Scale Bioseparations for the Biopharmaceutical Industry*; Taylor & Francis Group, LLC, 2007; pp 159–178.
- (2) Lee, E. K.; Kim, W. *Protein Crystallization for Large-Scale Bioseparation*; Marcel Dekker, 2003.
- (3) McPherson, A.; Gavira, J. a. *Acta Crystallogr. Sect. F, Struct. Biol. Commun.* **2014**, *F 70*, 2–20.
- (4) Schmidt, S.; Havekost, D.; Kaiser, K.; Kauling, J.; Henzler, H.-J. *Eng. Life Sci.* **2005**, *5* (3), 273–276.
- (5) Smejkal, B.; Helk, B.; Rondeau, J.-M.; Anton, S.; Wilke, A.; Scheyerer, P.; Fries, J.; Hekmat, D.; Weuster-Botz, D. *Biotechnol. Bioeng.* **2013**, *110* (7), 1956–1963.
- (6) Thommes, J.; Etzel, M. *Biotechnol. Prog.* **2007**, *23*, 42–45.
- (7) Neugebauer, P.; Khinast, J. G. *Cryst. Growth Des.* **2015**, *15*, 1089–1095.
- (8) Shenoy, B.; Wang, Y.; Shan, W.; Margolin, A. L. *Biotechnol. Bioeng.* **2001**, *73*, 358–369.
- (9) Smejkal, B.; Agrawal, N. J.; Helk, B.; Schulz, H.; Giffard, M.; Mechelke, M.; Ortner, F.; Heckmeier, P.; Trout, B. L.; Hekmat, D. *Biotechnol. Bioeng.* **2013**, *110* (9), 2452–2461.
- (10) Jacobsen, C.; Garside, J.; Hoare, M. *Biotechnol. Bioeng.* **1998**, *57*, 667–675.
- (11) Huettmann, H.; Zich, S.; Berkemeyer, M.; Buchinger, W.; Jungbauer, A. *Chem. Eng. Sci.* **2015**, *126*, 341–348.
- (12) Hekmat, D.; Hebel, D.; Schmid, H.; Weuster-Botz, D. *Process Biochem.* **2007**, *42* (12), 1649–1654.
- (13) Anderson, M. J.; Hansen, C. L.; Quake, S. R. *PNAS* **2006**, *103* (45), 16746–16751.


- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- (14) Asherie, N. *Methods* **2004**, *34* (3), 266–272.
- (15) Hebel, D.; Huber, S.; Stanislawski, B.; Hekmat, D. *J. Biotechnol.* **2013**, *166* (4), 206–211.
- (16) Parambil, J. V.; Schaepertoens, M.; Williams, D. R.; Heng, J. Y. Y. *Cryst. Growth Des.* **2011**, *11* (10), 4353–4359.
- (17) Russell A. Judge, Michael R. Johns, E. T. W. *Biotechnol. Bioeng.* **1995**, *48* (4), 316–323.
- (18) Yaoi, M.; Adachi, H.; Takano, K.; Matsumura, H.; Inoue, T.; Mori, Y.; Sasaki, T. *Jpn. J. Appl. Phys.* **2004**, *43* (10A), 1318.
- (19) Murai, R.; Yoshikawa, H. Y.; Kawahara, H.; Maki, S.; Sugiyama, S.; Kitatani, T.; Adachi, H.; Takano, K.; Matsumura, H.; Murakami, S.; Inoue, T.; Sasaki, T.; Mori, Y. *J. Cryst. Growth* **2008**, *310* (7-9), 2168–2172.
- (20) Lu, Q.-Q.; Yin, D. C.; Liu, Y. M.; Wang, X. K.; Yang, P. F.; Liu, Z. T.; Shang, P. *J. Appl. Crystallogr.* **2010**, *43*, 473–482.
- (21) Vekilov, P. G.; Rosenberger, F. *J. Cryst. Growth* **1998**, *186* (1-2), 251–261.
- (22) Marc Pusey; Witherow, W.; Naumann, R. *J. Cryst. Growth* **1988**, *90* (1-3), 105–111.
- (23) Harrison, R.; Todd, P.; Rudge, S.; Petrides, D. *Bioseparation Science and Engineering*; Press, O. U., Ed.; New York, 2015.
- (24) Carbone, M. N.; Etzel, M. R. *Biotechnol. Bioeng.* **2006**, *93* (6), 1221–1224.
- (25) Lorber, B.; Skouria, M.; Munch, J.-P.; Giegé, R. *J. Cryst. Growth* **1993**, *128* (1-4), 1203–1211.
- (26) Judge, R. a.; Forsythe, E. L.; Pusey, M. L. *Biotechnology and Bioengineering*. 1998, pp 776–785.
- (27) Takakura, T.; Ito, T.; Yagi, S.; Notsu, Y.; Itakura, T.; Nakamura, T.; Inagaki, K.;

- 1
2
3 Esaki, N.; Hoffman, R. M.; Takimoto, A. *Appl. Microbiol. Biotechnol.* **2006**, *70*
4
5 (2), 183–192.
6
7
8 (28) Lee, T.; Vaghjiani, J.; Lye, G.; Turner, M. *Enzyme Microb. Technol.* **2000**, *26*
9
10 (8), 582–592.
11
12 (29) Giffard, M.; Ferté, N.; Ragot, F.; El Hajji, M.; Castro, B.; Bonneté, F. *PLoS One*
13
14 **2011**, *6* (5), e19013.
15
16
17 (30) Zang, Y.; Kammerer, B.; Eisenkolb, M.; Lohr, K.; Kiefer, H. *PLoS One* **2011**, *6*
18
19 (9), e25282.
20
21
22 (31) Trilisky, E.; Gillespie, R.; Osslund, T. D.; Vunnum, S. *Biotechnology Progress*.
23
24 2011, pp 1054–1067.
25
26
27 (32) Ferreira, A.; Rocha, F.; Teixeira, J.A.; Vicente, A. Apparatus for mixing
28
29 improvement based on oscillatory flow reactors provided with smooth periodic
30
31 constrictions. WO/2015/056156, 2014.
32
33
34 (33) Harvey, A.; Mackley, M. R.; Reis, N.; Teixeira, J. A.; Vicente, A. A. In *30th*
35
36 *Conference SSCHE, Tatranské Matliare (SK), 26 – 30 May; 2003; pp 26–30.*
37
38
39 (34) Ferreira, A.; Teixeira, J. A.; Rocha, F. *Chem. Eng. J.* **2015**, *262*, 499–508.
40
41
42 (35) Castro, F.; Ferreira, A.; Rocha, F.; Vicente, A.; Teixeira, J. A. *AIChE J.* **2013**, *59*
43
44 (12), 4483–4493.
45
46
47 (36) Castro, F.; Ferreira, A.; Rocha, F.; Vicente, A.; Anto, J. *Ind. Eng. Chem. Res.*
48
49 **2013**, *52*, 9816–9821.
50
51
52 (37) Jiang, S.; Ter Horst, J. H. *Cryst. Growth Des.* **2011**, *11*, 256–261.
53
54
55 (38) Di Profio, G. Di; Curcio, E.; Cassetta, A.; Lamba, D.; Drioli, E. *J. Cryst. Growth*
56
57 **2003**, *257*, 359–369.
58
59
60 (39) Forsythe, E. L.; Judge, R. a.; Pusey, M. L. *J. Chem. Eng. Data* **1999**, *44* (3), 637–
640.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- (40) Martins, P. M.; Rocha, F.; Damas, A. M. *PLoS One* **2008**, *3* (4), e1998.
- (41) Crespo, R.; Martins, P. M.; Gales, L.; Rocha, F.; Damas, A. M. *J. Appl. Crystallogr.* **2010**, *43* (6), 1419–1425.
- (42) Bhamidi, V.; Skrzypczak-Jankun, E.; Schall, C. a. *Journal of Crystal Growth*. 2001, pp 77–85.
- (43) Tait, S.; White, E. T.; Litster, J. D. *Cryst. Growth Des.* **2009**, *9* (5), 2198–2206.
- (44) McPherson, A. *Crystallization of Biological Macromolecules*. Cold Spring Harbor, Ed. New York, 1999.
- (45) Kusters, K. A.; Wijers, J. G.; Thoenes, D. *Chem. Eng. Sci.* **1997**, *52* (1), 107–121.
- (46) Thomas, C. R.; Geer, D. *Biotechnol. Lett.* **2010**, *33* (3), 443–456.
- (47) Bee, J. S.; Stevenson, J. L.; Mehta, B.; Svitel, J.; Pollastrini, J.; Platz, R.; Freund, E.; Carpenter, J. F.; Randolph, T. W. *Biotechnol. Bioeng.* **2009**, *103* (5), 936–943.
- (48) Sandwick, R. K.; Schray, K. J. *J. Colloid Interface Sci.* **1987**, *115* (1), 130–138.
- (49) Caussette, M.; Gaunand, A.; Planche, H.; Colombié, S.; Monsan, P.; Lindet, B. *Enzyme Microb. Technol.* **1999**, *24* (7), 412–418.
- (50) Caussette, M.; Gaunand, A.; Planche, H.; Monsan, P.; Lindet, B. *Ann. New York Acad. Sci.* **1997**, *864*, 228–233.
- (51) Colombié, S.; Gaunand, A.; Lindet, B. *Enzyme Microb. Technol.* **2001**, *28* (9-10), 820–826.
- (52) Postel, C.; Abillon, O.; Desbat, B. *J. Colloid Interface Sci.* **2003**, *266* (1), 74–81.

1
2
3 **For Table of Contents Use only:**
4
5
6
7
8
9
10

11 **Table of Contents Graphic:**
12
13



28 **Synopsis**

29
30
31 The applicability of a novel meso oscillatory flow reactor for protein crystallization as a
32 process step was evaluated. A lysozyme phase diagram was derived and induction times
33 were measured. Reduction of the metastability zone and fast crystallization onsets were
34 verified, which may be particularly relevant for proteins with a limited range of
35 crystallization conditions and for industrial processes.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Schematic representation of the experimental set-up for lysozyme crystallization experiments with D - internal tube diameter; d_0 - internal diameter in the constrictions; L_1 - convergent-divergent section length; L_2 - straight section length; R_c - radius of the curvature of the sidewall of the convergent section and R_d - radius of the curvature of the sidewall of the divergent section.

65x124mm (300 x 300 DPI)




Figure 2. Schematic representation of the procedure employed for the generation of lysozyme phase diagram in the meso-OFR at 20 °C and pH 4.7 and under agitation conditions of $f = 1.83$ Hz and $x_0 = 4$ mm. 121x55mm (300 x 300 DPI)




Figure 3. Typical turbidity profile obtained during crystallization experiments (lysozyme 30 mg.mL⁻¹, NaCl 4% (w/v), pH 4.7 and T = 20 °C and under agitation conditions of f = 1.83 Hz and x₀ = 4 mm).
43x38mm (300 x 300 DPI)




Figure 4. Lysozyme phase behavior in the meso-OFR at pH 4.7 and 20 °C under agitation conditions of $f = 1.83$ Hz and $x_0 = 4$ mm.
39x25mm (300 x 300 DPI)




Figure 5. Lysozyme crystals obtained in the meso-OFR at pH 4.7 and 20 °C under agitation conditions of $f = 1.83$ Hz and $x_0 = 4$ mm. Lysozyme concentrations used are mentioned in each picture. 139x89mm (300 x 300 DPI)




Figure 6. Linearized metastability and solubility curves at 20 °C and pH 4.7 and under agitation conditions of $f = 1.83$ Hz and $x_0 = 4$ mm. Solubility and metastability curves were obtained by curve fitting from data reported in the literature³⁹⁻⁴¹.
126x82mm (300 x 300 DPI)




Figure 7. Lysozyme phase diagram in the meso-OFR at pH 4.7 and 20 °C under agitation conditions of $f = 1.83$ Hz and $x_0 = 4$ mm.
129x84mm (300 x 300 DPI)




Figure 8. Induction time as a function of the initial supersaturation S_i for different sodium chloride concentrations: 3% (w/v), 4% (w/v) and 5% (w/v). The error bars are standard deviations from at least three independent experiments. Smejkal et al. (2013) data was obtained in a stirred tank reactor of 6 mL for different stirrer speeds from 200 to 400 rpm with sodium chloride concentration of 4% (w/v) and lysozyme concentration of $50 \text{ mg}\cdot\text{mL}^{-1}$.
129x84mm (300 x 300 DPI)




Table of contents
102x44mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60